1. Summary {#s1}
==========

For many years, it has been recognized that myopia is highly heritable, but only recently has significant progress been made in dissecting the genetic background. In particular genome-wide association studies (GWAS) have successfully identified many common genetic variants associated with myopia and refractive error. It is clear that the trait is complex, with many genetic variants of small effect that are expressed in all retinal layers, often with a known function in neurotransmission or extracellular matrix. Exact mechanisms by which these genes function in a retina-to-sclera signaling cascade and other potential pathways remain to be elucidated. The prediction of myopia from genetic risk scores is improving, but whether this knowledge will affect clinical practice is yet unknown. This Committee recommends expanding large-scale genetic studies to further identify the molecular mechanisms through which environmental influences cause myopia (gene-by-environment effects), with an ultimate view to develop targeted treatments.

2. Key Points {#s2}
=============

1.  Refractive errors including myopia are caused by a complex interplay between many common genetic factors and environmental factors (near work, outdoor exposure).

2.  Early linkage studies and candidate gene studies have identified up to 50 loci and genes, but findings remained mostly unverified in replication studies.

3.  Large consortia performing GWAS enabled identification of common genetic variants associated with refractive error and myopia.

4.  The Consortium for Refractive Error and Myopia (CREAM) and 23andMe published findings from GWAS separately, and later combined studies in a GWAS meta-analysis, identifying 161 common variants for refractive error but explaining only approximately 8% of the phenotypic variance of this trait.

5.  Polygenic risk scores based on these variants indicate that persons at high genetic risk have an up to 40 times increased risk of myopia compared with persons at low genetic risk.

6.  The genetic loci appear to play a role in synaptic transmission, cell-cell adhesion, calcium ion binding, cation channel activity, and the plasma membrane. Many are light-dependent and related to cell-cycle and growth pathways.

7.  Pathway analysis confirms the hypothesis for a light-induced retina-to-sclera signaling pathway for myopia development.

8.  Genome-environment-wide interaction studies (GEWIS) assessing variant × education interaction effects identified nine other loci. Evidence for statistical interaction was also found; those at profound genetic risk with higher education appeared particularly susceptible to developing myopia.

9.  As most of the phenotypic variance of refractive errors is still unexplained, larger sample sizes are required with deeper coverage of the genome.

10. The ultimate aim of genetic studies is to discern the molecular signaling cascade and open up new avenues for intervention.

3. Introduction {#s3}
===============

Although myopia is strongly determined by environmental factors, the trait has long been known to run in families, suggesting a genetic predisposition. The heritability of refractive error, using spherical equivalent as a quantitative trait, has been determined in a number of families and twin studies.[@i1552-5783-60-3-M89-b01][@i1552-5783-60-3-M89-b02][@i1552-5783-60-3-M89-b03][@i1552-5783-60-3-M89-b04][@i1552-5783-60-3-M89-b05][@i1552-5783-60-3-M89-b06][@i1552-5783-60-3-M89-b07]--[@i1552-5783-60-3-M89-b08] The estimates resulting from these studies calculated heritabilities from 15% to 98%.[@i1552-5783-60-3-M89-b05],[@i1552-5783-60-3-M89-b07][@i1552-5783-60-3-M89-b08][@i1552-5783-60-3-M89-b09]--[@i1552-5783-60-3-M89-b10] However, it is important to note that this does not necessarily imply that most refractive error is genetic; familial clustering also can be determined by other factors.[@i1552-5783-60-3-M89-b11]

Like many other traits, common myopia has a complex etiology that is influenced by an interplay of genetic and environmental factors.[@i1552-5783-60-3-M89-b12] The current evidence, as summarized in this review, indicates that it is likely to be caused by many genes, each contributing a small effect to the overall myopia risk. The evidence for this has been confirmed by large GWAS.[@i1552-5783-60-3-M89-b01][@i1552-5783-60-3-M89-b02][@i1552-5783-60-3-M89-b03][@i1552-5783-60-3-M89-b04]--[@i1552-5783-60-3-M89-b05],[@i1552-5783-60-3-M89-b07],[@i1552-5783-60-3-M89-b13],[@i1552-5783-60-3-M89-b14] Several high, secondary syndromic forms of myopia, such as Marfan, Stickler, and Donnai-Barrow, form the exception, as they inherit predominantly in a Mendelian fashion with one single, highly penetrant, causal gene.[@i1552-5783-60-3-M89-b15]

This white paper aims to address the recent developments in genetic dissection of common refractive errors, in particular myopia. Up until the era of GWAS, identification of disease-associated genes relied on studies using linkage analysis in families or investigating variants in candidate genes. In myopia, these were singularly unsuccessful, and before 2009, there were no genes known for common myopia occurring in the general population. However, with the advent of GWAS, many refractive error genes associated with myopia have been identified, providing potential new insights into the molecular machinery underlying myopia, and perhaps promising leads for future therapies.

4. Heritability {#s4}
===============

Eighty years ago, Sir Duke-Elder was one of the first to recognize a "hereditary tendency to myopia."[@i1552-5783-60-3-M89-b16] Since then, evidence for familial aggregation has been delivered by various familial clustering, twin, and offspring studies,[@i1552-5783-60-3-M89-b01][@i1552-5783-60-3-M89-b02][@i1552-5783-60-3-M89-b03]--[@i1552-5783-60-3-M89-b04] and a genetic predisposition became more widely recognized. Strikingly, the estimates of myopia heritability vary widely among studies, with values as low as 10%[@i1552-5783-60-3-M89-b09],[@i1552-5783-60-3-M89-b10] found in a parent-offspring study in Eskimos, to as high as 98% in a study of female twin pairs[@i1552-5783-60-3-M89-b05],[@i1552-5783-60-3-M89-b07],[@i1552-5783-60-3-M89-b08] ([Table 1](#i1552-5783-60-3-M89-t01){ref-type="table"}). Differences in study design and method of analysis may account for this, but it is also conceivable that the phenotypic variance determined by heritable factors is high in settings in which environmental triggers are limited, and low where they are abundant. Based on literature, heritability of myopia is probably between 60% and 80%.

###### 

Heritability Estimates of Refractive Error

  **Subjects**                                  **Study**                                            **Heritability Estimate (±SE or 95% CI)**
  --------------------------------------------- --------------------------------------------------- -------------------------------------------
  Monozygous and dizygous twin pairs            Dirani et al. 2006[@i1552-5783-60-3-M89-b06]                  0.88 ± 0.02 (men) (SE)
  Hammond et al. 2001^21^                       0.86 (0.83--0.89)                                   
  Lyhne et al. 2001[@i1552-5783-60-3-M89-b07]   0.89--0.94 (0.82--0.96)                             
  Sibling pair                                  Guggenheim et al. 2007[@i1552-5783-60-3-M89-b152]                0.90 (0.62--1.12)
  Peet et al. 2007[@i1552-5783-60-3-M89-b153]   0.69 (0.58--0.85)                                   
  Full pedigree                                 Klein et al. 2009^19^                                               0.62 ± 0.13
  Parent-offspring pair                         Lim et al. 2014[@i1552-5783-60-3-M89-b154]                       0.30 (0.27--0.33)

Variation in corneal curvature and axial length contribute to the degree of myopia.[@i1552-5783-60-3-M89-b17] Twin studies also estimated a high heritability for most of the individual biometric parameters.[@i1552-5783-60-3-M89-b18],[@i1552-5783-60-3-M89-b19] Correlations between corneal curvature and axial length were at least 64%,[@i1552-5783-60-3-M89-b20] suggesting a considerable genetic overlap between the parameters.

Studies addressing the inheritance structure of myopia and its endophenotypes identified several models, mostly a combination of additive genetic and environmental effects.[@i1552-5783-60-3-M89-b06],[@i1552-5783-60-3-M89-b18],[@i1552-5783-60-3-M89-b21],[@i1552-5783-60-3-M89-b22] Genome-wide complex trait analysis, using high-density genome-wide single-nucleotide polymorphism (SNP) genotype information, was performed in young children from the Avon Longitudinal Study of Parents and Children (ALSPAC), and results suggested that common SNPs explained approximately 35% of the variation in refractive error between unrelated subjects.[@i1552-5783-60-3-M89-b23] SNP heritability calculated by linkage disequilibrium score regression in the CREAM Consortium was 21% in European individuals but only 5% in Asian individuals, which could be due to the low representation of this ancestry.[@i1552-5783-60-3-M89-b24]

In conclusion, the genetic component of myopia and ocular biometry is well recognized, but its magnitude varies in studies depending on the population being studied, the study design, and the methodology. It is important to note that the recent global rise of myopia prevalence is unlikely to be due to genetic factors, but the degree of myopia may still be under genetic control.[@i1552-5783-60-3-M89-b25]

5. Linkage Studies {#s5}
==================

A number of linkage studies for myopia were performed in families and high-risk groups before the GWAS era ([Fig. 1](#i1552-5783-60-3-M89-f01){ref-type="fig"}).[@i1552-5783-60-3-M89-b26] Linkage studies have searched for cosegregation of genetic markers (such as cytosine-adenine \[CA\] repeats) with the trait through pedigrees, and has been successfully applied for many Mendelian disorders.[@i1552-5783-60-3-M89-b27] In families with an autosomal dominant inheritance pattern of myopia, this approach helped to identify several independent loci for (high) myopia: MYP 1 to 20,[@i1552-5783-60-3-M89-b26],[@i1552-5783-60-3-M89-b28][@i1552-5783-60-3-M89-b29]--[@i1552-5783-60-3-M89-b30] as well as several other loci.[@i1552-5783-60-3-M89-b31][@i1552-5783-60-3-M89-b32][@i1552-5783-60-3-M89-b33][@i1552-5783-60-3-M89-b34][@i1552-5783-60-3-M89-b35]--[@i1552-5783-60-3-M89-b36] Fine-mapping of several of these loci led to candidate genes, such as the *IGF1* gene located in the MYP3 locus.[@i1552-5783-60-3-M89-b12] Although validation of the same markers failed in these candidate genes, other variants appeared associated with common myopia, suggesting genetic overlap between Mendelian and complex myopia.[@i1552-5783-60-3-M89-b37] Linkage studies using a complex inheritance design found five additional loci.[@i1552-5783-60-3-M89-b38][@i1552-5783-60-3-M89-b39][@i1552-5783-60-3-M89-b40][@i1552-5783-60-3-M89-b41]--[@i1552-5783-60-3-M89-b42]

![Historic overview of myopia gene finding. Genes identified using WES are marked as purple. Other loci (linkage studies, GWAS) are marked as red.](i1552-5783-60-3-M89-f01){#i1552-5783-60-3-M89-f01}

With the development of new approaches for gene finding, linkage analysis with CA-markers became unfashionable. Nevertheless, segregation and linkage analysis of a variant or region in pedigrees is still a common procedure for fine-mapping or dissection of disease haplotypes.

6. Secondary Syndromic Myopia {#s6}
=============================

Myopia can accompany other systemic or ocular abnormalities. The secondary syndromic myopias are generally monogenic and have a wide spectrum of clinical presentations. [Table 2](#i1552-5783-60-3-M89-t02){ref-type="table"} summarizes the known syndromic conditions that present with myopia, and [Table 3](#i1552-5783-60-3-M89-t03){ref-type="table"} summarizes the known ocular conditions.[@i1552-5783-60-3-M89-b43] Among these disorders are many mental retardation syndromes, such as Angelman (Online Mendelian Inheritance in Man database \[OMIM\] \#105830), Bardet-Biedl (OMIM \#209900), and Cohen (OMIM \#216550) and Pitt-Hopkins syndrome (OMIM \#610954). Myopia also can be a characteristic feature in heritable connective tissue disorders, such as Marfan (OMIM \#154700), Stickler (OMIM \#108300, \#604841, \#614134, \#614284), and Weill-Marchesani syndrome (OMIM \#277600, \#608328, \#614819, \#613195), and several types of Ehlers-Danlos syndrome (OMIM \#225400, \#601776).

###### 

Overview of Secondary Syndromic Forms of Myopia: Systemic Syndromes Associated With Myopia

  **Title**                                                                            **Gene and Inheritance Pattern**
  ------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Acromelic frontonasal dysostosis                                                     *ZSWIM6* (AD)
  Alagille syndrome                                                                    *JAG1* (AD)
  Alport syndrome                                                                      *COL4A5 (*XLD); *COL4A3* (AR/AD)
  Angelman syndrome                                                                    *UBE3A* (IP); CH
  Bardet-Biedl syndrome                                                                *ARL6*; *BBS1*; *BBS2*; *BBS4*; *BBS5*; *BBS7*; *BBS9*; *BBS10*; *BBS12*; *CEP290*; *LZTFL1*; *MKKS*; *MKS1*; *SDCCAG8*; *TMEM67*; *TRIM32*; *TTC8*; *WDPCP* (AR)
  Beals syndrome                                                                       *FBN2* (AD)
  Beaulieu-Boycott-Innes syndrome                                                      *THOC6* (AR)
  Bohring-Opitz syndrome                                                               *ASXL1* (AD)
  Bone fragility and contractures; arterial rupture and deafness                       *PLOD3* (AR)
  Branchiooculofacial syndrome                                                         *TFAP2A* (AD)
  Cardiofaciocutaneous syndrome                                                        *MAP2K2* (AD)
  Cohen syndrome                                                                       *VPS13B* (AR)
  Cornelia de Lange syndrome                                                           *NIPBL* (AD); *HDAC8* (XLD)
  Cowden syndrome                                                                      *PTEN* (AD)
  Cranioectodermal dysplasia                                                           *IFT122* (AR)
  Cutis laxa                                                                           *ATP6V0A2*; *ALDH18A1* (AR)
  Danon disease                                                                        *LAMP2* (XLD)
  Deafness and myopia                                                                  *SLITRK6* (AR)
  Desanto-Shinawi syndrome                                                             *WAC* (AD)
  Desbuquois dysplasia                                                                 *CANT1* (AR)
  Donnai-Barrow syndrome                                                               *LRP2* (AR)
  DOORS                                                                                *TBC1D24* (AR)
  Ehlers-Danlos syndrome                                                               *COL5A1* (AD); *PLOD1* (AR); *CHST14* (AR); *ADAMTS2* (AR); *B3GALT6* (AR); *FKBP14* (AR)
  Emanuel syndrome                                                                     CH
  Fibrochondrogenesis                                                                  *COL11A1* (AR)
  Gyrate atrophy of choroid and retina with/without ornithinemia                       *OAT* (AR)
  Hamamy syndrome                                                                      *IRX5* (AR)
  Homocystinuria                                                                       *CBS* (AR)
  Joint laxity; short stature; myopia                                                  *GZF1* (AR)
  Kaufman oculocerebrofacial syndrome                                                  *UBE3B* (AR)
  Kenny-Caffey syndrome                                                                *FAM111A* (AD)
  Kniest dysplasia                                                                     *COL2A1* (AD)
  Knobloch syndrome                                                                    *COL18A1* (AR)
  Lamb-Shaffer syndrome                                                                *SOX5* (AD)
  Lethal congenital contracture syndrome                                               *ERBB3* (AR)
  Leukodystrophy                                                                       *POLR1C*; *POLR3A*; *POLR3B*; *GJC2* (AR)
  Linear skin defects with multiple congenital anomalies                               *NDUFB11*; *COX7B* (XLD)
  Loeys-Dietz syndrome                                                                 *TGFBR1*; *TGFBR2* (AD)
  Macrocephaly/megalencephaly syndrome                                                 *TBC1D7* (AR)
  Marfan syndrome                                                                      *FBN1* (AD)
  Marshall syndrome                                                                    *COL11A1* (AD)
  Microcephaly with/without chorioretinopathy; lymphedema; and/or mental retardation   *KIF11* (AD)
  Mohr-Tranebjaerg syndrome                                                            *TIMM8A* (XLR)
  Mucolipidosis                                                                        *GNPTAG* (AR)
  Muscular dystrophy                                                                   *TRAPPC11*; *POMT*; *POMT1*; *POMT2*; *POMGNT1*; *B3GALNT2*; *FKRP*; *DAG1*; *FKTN* (AR)
  Nephrotic syndrome                                                                   *LAMB2* (AR)
  Noonan syndrome                                                                      *A2ML1*; *BRAF*; *CBL*; *HRAS*; *KRAS*; *MAP2K1*; *MAP2K2*; *NRAS*; *PTPN11*; *RAF1*; *RIT1*; *SOS1*; *SHOC2*; *SPRED1* (AD)
  Oculocutaneous albinism                                                              *TYR* (AR)
  Oculodentodigital dysplasia                                                          *GJA1* (AR)
  Pallister-Killian syndrome                                                           CH
  Papillorenal syndrome                                                                *PAX2* (AD)
  Peters-plus syndrome                                                                 *B3GLCT* (AR)
  Pitt-Hopkins syndrome                                                                *TCF4* (AD)
  Pontocerebellar hypoplasia                                                           *CHMP1A* (AR)
  Poretti-Boltshauser syndrome                                                         *LAMA1* (AR)
  Prader-Willi syndrome                                                                *NDN* (PC); *SNRPN* (IP); CH
  Pseudoxanthoma elasticum                                                             *ABCC6* (AR)
  Renal hypomagnesemia                                                                 *CLDN16*; *CLDN19* (AR)
  SADDAN                                                                               *FGFR3* (AD)
  Schaaf-Yang syndrome                                                                 *MAGEL2* (AD)
  Schimke immunoosseous dysplasia                                                      *SMARCAL1* (AR)
  Schuurs-Hoeijmakers syndrome                                                         *PACS1* (AD)
  Schwartz-Jampel syndrome                                                             *HSPG2* (AR)
  Sengers syndrome                                                                     *AGK* (AR)
  Short stature; hearing loss; retinitis pigmentosa and distinctive facies             *EXOSC2* (AR)
  Short stature; optic nerve atrophy; and Pelger-Huet anomaly                          *NBAS* (AR)
  SHORT syndrome                                                                       *PIK3R1* (AD)
  Short-rib thoracic dysplasia with/without polydactyly                                *WDR19* (AR)
  Shprintzen-Goldberg syndrome                                                         *SKI* (AD)
  Singleton-Merten syndrome                                                            *IFIH1* (AD)
  Small vessel brain disease with/without ocular anomalies                             *COL4A1* (AD)
  Smith-Magenis syndrome                                                               *RAI1* (AD)
  Spastic paraplegia                                                                   *HACE1* (AR)
  Split hand/foot malformation                                                         CH
  Stickler syndrome                                                                    *COL2A1* (AD); *COL11A1* (AD); *COL9A1* (AR); *COL9A2* (AR)
  Syndromic mental retardation                                                         *SETD5* (AD); *MBD5* (AD); *USP9X* (XLD); *NONO* (XLR); *RPL10* (XLR); *SMS* (XLR); *ELOVL4* (AR); *KDM5C* (XLR)
  Syndromic microphthalmia                                                             *OTX2*; *BMP4* (AD)
  Temtamy syndrome                                                                     *C12orf57* (AR)
  White-Sutton syndrome                                                                *POGZ* (AD)
  Zimmermann-Laband syndrome                                                           *KCNH1* (AD)

AD, autosomal dominant; AR, autosomal recessive; CH, chromosomal; IP, imprinting defect; XLD, × linked dominant; XLR, × linked recessive.

###### 

Overview of Secondary Syndromic Forms of Myopia: Ocular Syndromes Associated With Myopia

  **Title**                                                                              **Gene and Inheritance Pattern**
  -------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  Achromatopsia                                                                          *CNGB3* (AR)
  Aland Island eye disease                                                               *GPR143* (XLR)
  Anterior-segment dysgenesis                                                            *PITX3* (AD)
  Bietti crystalline corneoretinal dystrophy                                             *CYP4V2* (AD)
  Blue cone monochromacy                                                                 *OPN1LW*; *OPN1MW* (XLR)
  Brittle cornea syndrome                                                                *ZNF469*; *PRDM5* (AR)
  Cataract                                                                               *BFSP2*; *CRYBA2*; *EPHA2* (AD)
  Colobomatous macrophthalmia with microcornea                                           CH
  Cone dystrophy                                                                         *KCNV2* (AD)
  Cone rod dystrophy                                                                     *C8orf37* (AR); *RAB28* (AR); *RPGR* (XLR); *CACNA1F* (XLR)
  Congenital microcoria                                                                  CH
  Congenital stationary night blindness                                                  *NYX* (XLR); *CACNA1F* (XLR); *GRM6* (AR); *SLC24A1* (AR); *LRIT3* (AR); *GNB3* (AR); *GPR179* (AR)
  Ectopia lentis et pupillae                                                             *ADAMTSL4* (AR)
  High myopia with cataract and vitreoretinal degeneration                               *P3H2* (AR)
  Keratoconus                                                                            *VSX1* (AD)
  Leber congenital amaurosis                                                             *TULP1* (AR)
  Microcornea, myopic chorioretinal atrophy, and telecanthus                             *ADAMTS18* (AR)
  Microspherophakia and/or megalocornea, with ectopia lentis and/or secondary glaucoma   *LTBP2* (AR)
  Ocular albinism                                                                        *OCA2* (AR)
  Primary open angle glaucoma                                                            *MYOC*; *OPTN* (AD)
  Retinal cone dystrophy                                                                 *KCNV2* (AR)
  Retinal dystrophy                                                                      *C21orf2* (AR); *TUB* (AR)
  Retinitis pigmentosa                                                                   *RP1* (AD); *RP2* (XLR); *RPGR* (XLR); *TTC8* (AR)
  Sveinsson chorioretinal atrophy                                                        *TEAD1* (AD)
  Vitreoretinopathy                                                                      *ZNF408* (AD)
  Wagner vitreoretinopathy                                                               *VCAN* (AD)
  Weill-Marchesani syndrome                                                              *ADAMTS10* (AR); *FBN1* (AD); *LTBP2* (AR); *ADAMTS17* (AR)

A number of inherited retinal dystrophies also present with myopia, most strikingly X-linked retinitis pigmentosa caused by mutations in the *RPGR*-gene (retinal G protein--coupled receptor) (see Ref. [@i1552-5783-60-3-M89-b44] for common gene acronyms) and congenital stationary night blindness.[@i1552-5783-60-3-M89-b45] Other eye disorders accompanied by myopia are ocular albinism (OMIM \#300500) and Wagner vitreoretinopathy (OMIM \#143200).

Most genes causing syndromic forms of myopia have not (yet) been implicated in common forms of myopia, except for collagen type II alpha 1 chain (*COL2A1*)[@i1552-5783-60-3-M89-b46],[@i1552-5783-60-3-M89-b47] and fibrilin 1 (*FBN1*).[@i1552-5783-60-3-M89-b24],[@i1552-5783-60-3-M89-b48] However, a recent study screened polymorphisms located in and around genes known to cause rare syndromic myopia, and found them to be overrepresented in GWASs on refractive error and myopia.[@i1552-5783-60-3-M89-b49] This implies that although rare, pathogenic mutations in these genes have a profound impact on the eye; more benign polymorphisms may have only subtle effects on ocular biometry and refractive error.

7. Candidate Gene Studies {#s7}
=========================

Candidate genes are generally selected based on their known biological, physiological, or functional relevance to the disease. Although sometimes highly effective, this approach is limited by its reliance on existing knowledge. Another caveat not specific for this approach is that genetic variability across populations can make it difficult to distinguish normal variation from disease-associated variation.[@i1552-5783-60-3-M89-b13] In addition, candidate gene studies are very prone to publication bias, and therefore published results are highly selected.

Numerous genes have been investigated in candidate gene studies for refractive error traits. [Table 4](#i1552-5783-60-3-M89-t04){ref-type="table"} summarizes all studies that reported statistically significant associations for myopia or ocular refraction. Genes that encode collagens (*COL1A1*, *COL2A1*),[@i1552-5783-60-3-M89-b46],[@i1552-5783-60-3-M89-b47] transforming growth factors (*TGFβ1*, *TGFβ2*, *TGFβ-*induced factor homeobox 1 \[*TGIF1*\]),[@i1552-5783-60-3-M89-b50][@i1552-5783-60-3-M89-b51]--[@i1552-5783-60-3-M89-b52] hepatocyte growth factor and its receptor (*HGF*, *CMET*),[@i1552-5783-60-3-M89-b53][@i1552-5783-60-3-M89-b54]--[@i1552-5783-60-3-M89-b55] insulin-like growth factor (*IGF1*),[@i1552-5783-60-3-M89-b56],[@i1552-5783-60-3-M89-b57] matrix metalloproteinases (*MMP1*, *MMP2*, *MMP3*, *MMP9*, *MMP10*),[@i1552-5783-60-3-M89-b58],[@i1552-5783-60-3-M89-b59] the lumican gene (*LUM*),[@i1552-5783-60-3-M89-b60] and the ocular developmental gene *PAX6*,[@i1552-5783-60-3-M89-b61] all showed promise in candidate gene studies. Unfortunately, like myopia linkage studies, these studies generally lacked validation by independent studies.[@i1552-5783-60-3-M89-b62] Meta-analyses combining data from several candidate gene studies provided evidence for a consistent association between a single SNP in the *PAX6* gene and extreme and high myopia.[@i1552-5783-60-3-M89-b63] Meta-analyses of the *LUM* and *IGF1* genes did not confirm an association.[@i1552-5783-60-3-M89-b64],[@i1552-5783-60-3-M89-b65]

###### 

Summary of Candidate Gene Studies Reporting Positive Association Results With Myopia

  **Gene**   **Study**                                                                 **Ethnicity**    **Independent Confirmation**   **Replication in GWAS**
  ---------- ------------------------------------------------------------------------- --------------- ------------------------------ -------------------------
  *APLP2*    Tkatchenko et al. 2015[@i1552-5783-60-3-M89-b131]                         Caucasian                     --                          --
  *BMP2K*    Liu et al. 2009[@i1552-5783-60-3-M89-b155]                                Chinese                       --                          --
  *CHRM1*    Lin et al. 2009[@i1552-5783-60-3-M89-b156]                                Han Chinese                 X^157^                        --
  *CHRM1*    Guggenheim et al. 2010[@i1552-5783-60-3-M89-b158]                         Caucasian                   X^157^                        --
  *CMET*     Khor et al. 2009[@i1552-5783-60-3-M89-b55]                                Chinese                       --                          --
  *COL1A1*   Inamori et al. 2007[@i1552-5783-60-3-M89-b159]                            Japanese                      --                          --
  *COL2A1*   Mutti et al. 2007[@i1552-5783-60-3-M89-b46]                               Caucasian                     --                          --
  *COL2A1*   Metlapally et al. 2009[@i1552-5783-60-3-M89-b47]                          Caucasian                     --                          --
  *CRYBA4*   Ho et al. 2012[@i1552-5783-60-3-M89-b160]                                 Chinese                       --                          --
  *HGF*      Han et al. 2006[@i1552-5783-60-3-M89-b54]                                 Han Chinese                   --                          --
  *HGF*      Yanovitch et al. 2009[@i1552-5783-60-3-M89-b161]                          Caucasian                     --                          --
  *HGF*      Veerappan et al. 2010[@i1552-5783-60-3-M89-b53]                           Caucasian                     --                          --
  *IGF1*     Metlapally et al. 2010[@i1552-5783-60-3-M89-b57]                          Caucasian                     --                          --
  *LUM*      Wang et al. 2006[@i1552-5783-60-3-M89-b60]                                Chinese                       --                          --
  *LUM*      Chen et al. 2009[@i1552-5783-60-3-M89-b162]                               Han Chinese                   --                          --
  *LUM*      Lin et al. 2010[@i1552-5783-60-3-M89-b164]                                Chinese                       --                          --
  *LUM*      Guggenheim et al. 2010[@i1552-5783-60-3-M89-b158]                         Caucasian                     --                          --
  *MFN1*     Andrew et al. 2008[@i1552-5783-60-3-M89-b164]                             Caucasian                   X^165^                        --
  *MMP1*     Wojciechowski et al. 2010[@i1552-5783-60-3-M89-b130]                      Amish                         --                          --
  *MMP1*     Wojciechowski et al. 2013[@i1552-5783-60-3-M89-b59]                       Caucasian                     --                          --
  *MMP10*    Wojciechowski et al. 2013[@i1552-5783-60-3-M89-b59]                       Caucasian                     --                          --
  *MMP2*     Wojciechowski et al. 2010[@i1552-5783-60-3-M89-b130]                      Amish                         --                          --
  *MMP2*     Wojciechowski et al. 2013[@i1552-5783-60-3-M89-b59]                       Caucasian                     --                          --
  *MMP3*     Hall et al. 2009[@i1552-5783-60-3-M89-b58]                                Caucasian                     --                          --
  *MMP9*     Hall et al. 2009[@i1552-5783-60-3-M89-b58]                                Caucasian                     --                          --
  *MYOC*     Tang et al. 2007[@i1552-5783-60-3-M89-b63]                                Chinese                       --                          --
  *MYOC*     Vatavuk et al. 2009[@i1552-5783-60-3-M89-b167]                            Caucasian                     --                          --
  *MYOC*     Zayats et al. 2009[@i1552-5783-60-3-M89-b168]                             Caucasian                     --                          --
  *PAX6*     Tsai et al. 2008[@i1552-5783-60-3-M89-b169]                               Chinese                       --                          --
  *PAX6*     Ng et al. 2009[@i1552-5783-60-3-M89-b170]                                 Han Chinese                   --                          --
  *PAX6*     Han et al. 2009[@i1552-5783-60-3-M89-b171]                                Han Chinese                   --                          --
  *PAX6*     Miyake et al. 2012[@i1552-5783-60-3-M89-b172]                             Japanese                      --                          --
  *PAX6*     Kanemaki et al. 2015[@i1552-5783-60-3-M89-b173]                           Japanese                      --                          --
  *PSARL*    Andrew et al. 2008[@i1552-5783-60-3-M89-b164]                             Caucasian                     --                          --
  *SOX2T*    Andrew et al. 2008[@i1552-5783-60-3-M89-b164]                             Caucasian                     --               
  *TGFβ1*    Lin et al. 2006[@i1552-5783-60-3-M89-b50]                                 Chinese                       --                         X^24^
  *TGFβ1*    Zha et al. 2009[@i1552-5783-60-3-M89-b174]                                Chinese                       --                         X^24^
  *TGFβ1*    Khor et al. 2010[@i1552-5783-60-3-M89-b56]                                Chinese                       --                         X^24^
  *TGFβ1*    Rasool et al. 2013[@i1552-5783-60-3-M89-b175]                             Indian                        --                         X^24^
  *TGFβ2*    Lin et al. 2009[@i1552-5783-60-3-M89-b51]                                 Han Chinese                   --                          --
  *TGIF*     Lam et al. 2003[@i1552-5783-60-3-M89-b52]                                 Chinese                       --                          --
  *TGIF1*    Ahmed et al. 2014[@i1552-5783-60-3-M89-b52],[@i1552-5783-60-3-M89-b176]   Indian                        --                          --
  *LAMA1*    Zhao et al. 2011[@i1552-5783-60-3-M89-b177]                               Chinese                       --                          --
  *UMODL1*   Nishizaki et al. 2009[@i1552-5783-60-3-M89-b178]                          Japanese                      --                          --

X indicates independent conformation or replication in GWAS study with reference included.

8. Genome-Wide Association Studies {#s8}
==================================

Since the first GWAS in 2005,[@i1552-5783-60-3-M89-b66] more than 3000 human GWAS have examined more than 1800 diseases and traits, and thousands of SNP associations have been found. This has greatly augmented our knowledge of human genetics and complex diseases.[@i1552-5783-60-3-M89-b14] GWAS genotyping arrays can identify millions of SNPs across the genome in one assay; these variants are generally common and mostly not protein coding. Effect sizes of SNPs associated with disease are mostly small, requiring very large study samples to reach statistical significance.[@i1552-5783-60-3-M89-b13],[@i1552-5783-60-3-M89-b14] Fortunately, technological advances have lowered the costs of genotyping considerably over the years,[@i1552-5783-60-3-M89-b67] and GWAS on hundreds of thousands of individuals are becoming more common.

8.1 GWAS of Refractive Errors and Myopia {#s8a}
----------------------------------------

GWAS for myopia have been performed using myopia as a dichotomous outcome or refractive error as a quantitative trait. Several endophenotypes have also been considered: spherical equivalent, axial length, corneal curvature, and age of diagnosis of myopia.

[Figure 2](#i1552-5783-60-3-M89-f02){ref-type="fig"} provides an overview of all associated loci and nearby genes, their frequency, and effect sizes.

![Effect sizes of common and rare variants for myopia and refractive error. Overview of SNPs and annotated genes found in the most recent GWAS meta-analysis.[@i1552-5783-60-3-M89-b24] The x-axis displays the minor allele frequency of each SNP; y-axis displays the effect size of the individual SNP in diopters; We transformed the z-scores of the fixed effect meta-analysis between CREAM (refractive error) and 23andMe (age of diagnosis of myopia) into effect sizes in diopters with the following formula[@i1552-5783-60-3-M89-b24]: $\begin{document}\newcommand{\bialpha}{\boldsymbol{\alpha}}\newcommand{\bibeta}{\boldsymbol{\beta}}\newcommand{\bigamma}{\boldsymbol{\gamma}}\newcommand{\bidelta}{\boldsymbol{\delta}}\newcommand{\bivarepsilon}{\boldsymbol{\varepsilon}}\newcommand{\bizeta}{\boldsymbol{\zeta}}\newcommand{\bieta}{\boldsymbol{\eta}}\newcommand{\bitheta}{\boldsymbol{\theta}}\newcommand{\biiota}{\boldsymbol{\iota}}\newcommand{\bikappa}{\boldsymbol{\kappa}}\newcommand{\bilambda}{\boldsymbol{\lambda}}\newcommand{\bimu}{\boldsymbol{\mu}}\newcommand{\binu}{\boldsymbol{\nu}}\newcommand{\bixi}{\boldsymbol{\xi}}\newcommand{\biomicron}{\boldsymbol{\micron}}\newcommand{\bipi}{\boldsymbol{\pi}}\newcommand{\birho}{\boldsymbol{\rho}}\newcommand{\bisigma}{\boldsymbol{\sigma}}\newcommand{\bitau}{\boldsymbol{\tau}}\newcommand{\biupsilon}{\boldsymbol{\upsilon}}\newcommand{\biphi}{\boldsymbol{\phi}}\newcommand{\bichi}{\boldsymbol{\chi}}\newcommand{\bipsi}{\boldsymbol{\psi}}\newcommand{\biomega}{\boldsymbol{\omega}}SE = {\sqrt{1 \over 2N*MAF(1-MAF)}}\end{document}$.](i1552-5783-60-3-M89-f02){#i1552-5783-60-3-M89-f02}

### 8.1.1 Myopia Case-Control Design {#s8a1}

The case-control design using (high) myopia as a dichotomous outcome has been especially popular in East Asia. The first case-control GWAS was performed in a Japanese cohort in 2009.[@i1552-5783-60-3-M89-b68] It comprised 830 cases of pathologic myopia (defined as axial length \>26 mm) and 1911 controls from the general population. The strongest association was located at 11q24.1, approximately 44 kb upstream of the BH3-like motif containing, cell death inducer (*BLID*) gene, and conferred odds of higher myopia of 1.37 (95% confidence interval \[CI\] 1.21--1.54). Subsequently, a GWAS meta-analysis of two ethnic Chinese cohorts was performed in 287 cases of high myopia (defined as ≤ −6 diopters \[D\]) and 673 controls. The strongest association was for an intronic SNP within the catenin delta 2 (*CTNND2*) gene on 5p15.2.[@i1552-5783-60-3-M89-b69] Neither of these associations met the conventional GWAS threshold (*P* ≤ 5 × 10^−8^) for statistical significance due to small sample size. Nevertheless, the locus at 5p15 encompassing the *CTNND2* gene was later confirmed by other Asian studies.[@i1552-5783-60-3-M89-b70][@i1552-5783-60-3-M89-b71]--[@i1552-5783-60-3-M89-b72]

Li et al.[@i1552-5783-60-3-M89-b73] studied 102 high myopia cases (defined as ≤ −8 D with retinopathy) and 335 controls in an ethnic Chinese population. The strongest association (*P* = 7.70 × 10^−13^) was a high-frequency variant located in a gene desert within the MYP11 myopia linkage locus on 4q25. In a similar ethnic Han Chinese population of 419 high myopia cases (≤ −6 D) and 669 controls, Shi et al.[@i1552-5783-60-3-M89-b73],[@i1552-5783-60-3-M89-b74] identified the strongest association (*P* = 1.91 × 10^−16^) at an intronic, high-frequency variant within the mitochondrial intermediate peptidase (*MIPEP*) gene on 13q12. Neither hit has been replicated, even in studies with similar design, phenotypic definition, and ethnic background.

In 2013, two papers reported loci for high myopia in Asian populations and these were successfully replicated. Shi et al.[@i1552-5783-60-3-M89-b75] studied a Han Chinese population of 665 cases with high myopia (≤ −6 D) and 960 controls. Following two-stage replication in three independent cohorts, the most significantly associated variant (*P* = 8.95 × 10^−14^) was identified in the vasoactive intestinal peptide receptor 2 (*VIPR2*) gene within the MYP4 locus, followed by three other variants within a linkage disequilibrium block in the syntrophin beta 1 (*SNTB1*) gene (*P* = 1.13 × 10^−8^ to 2.13 × 10^−11^). Khor et al.[@i1552-5783-60-3-M89-b76] reported a meta-analysis of four GWAS including 1603 cases of "severe" myopia and 3427 controls of East Asian ethnicity. After replication and meta-analysis, the *SNTB1* gene was confirmed, and a novel variant within the *ZFHX1B* gene (also known as zinc finger E-box binding homeobox 2 \[*ZEB2*\]) reached genome-wide significance (*P* = 5.79 × 10^−10^).

In 2018, a pathologic myopia case-control study was performed in cohorts of Asian ancestry, using participants with −5.00 D or more myopia with an axial length \>26 mm. Fundus photographs were graded pathologic or nonpathologic (*N*~cases~ = 828, *N*~controls~ = 3624). The researchers found a novel genetic variant in the coiled-coil domain containing 102B (*CCDC102B*) locus (*P* = 1.46 × 10^−10^), which was subsequently replicated in an independent cohort (*P* = 2.40 × 10^−6^). This gene is strongly expressed in the RPE and choroid. As myopic maculopathy is the primary cause of blindness in high myopia, further functional investigation could be valuable.[@i1552-5783-60-3-M89-b77]

In Europe, a French case-control GWAS was performed on 192 high myopia cases (≤ −6 D) and 1064 controls, and a suggestive association was identified within the MYP10 linkage locus, 3 kb downstream of protein phosphatase 1 regulatory subunit 3B (*PPP1R3B*). However, this association did not reach genome-wide statistical significance, and no previously reported loci were replicated.[@i1552-5783-60-3-M89-b78] Later, in 2016, the direct-to-consumer genetic testing company 23andMe (Mountain View, CA, USA) published a large GWAS on self-reported myopia (*N*~cases~ = 106,086 and N~controls~ *=* 85,757; all European ancestry), and identified more than 100 novel loci for myopia.[@i1552-5783-60-3-M89-b79] Because this study was intended for association analyses between traits, precise locus definitions, post-GWAS quality control, and replication were not performed.

### 8.1.2 Quantitative Design on Spherical Equivalent {#s8a2}

Studies that considered refractive error as a quantitative trait, and included subjects from the general population who displayed the entire range of refractive error, have been more successful. In 2010, the first GWAS for spherical equivalent were carried out in two European populations: a British cohort of 4270 individuals and a Dutch cohort of 5328 individuals.[@i1552-5783-60-3-M89-b80],[@i1552-5783-60-3-M89-b81] Two loci surpassed the GWAS threshold and were replicated: one near the *RASGFR1* gene on 15q25.1 (*P* = 2.70 × 10^−09^) and the other near *GJD2* on 15q14 (*P* = 2.21 × 10^−14^). Subsequently, a meta-analysis was performed on 7280 individuals with refractive error from five different cohorts, which included various ethnic populations across different continents, and findings were replicated in 26,953 samples. A novel locus including the *RBFOX1* gene on chromosome 16 reached genome-wide significance (*P* = 3.9 × 10^−9^).[@i1552-5783-60-3-M89-b82]

These collaborations paved the way for the formation of a large consortium to achieve higher statistical power for gene finding. CREAM was established in 2010 and included researchers and cohorts from the United States, Europe, Asia, and Australia. Its first collaborative work was replication of SNPs in the previously identified 15q14 loci.[@i1552-5783-60-3-M89-b83] Other studies followed this approach, and confirmed 15q14 as well as the 15q25 locus.[@i1552-5783-60-3-M89-b84],[@i1552-5783-60-3-M89-b85] Subsequently, CREAM conducted a GWAS meta-analysis based on HapMapII imputation[@i1552-5783-60-3-M89-b86] with 35 participating studies comprising 37,382 individuals of European descent and 12,332 of Southeast Asian ancestry with data on GWAS and spherical equivalent. This study enabled replication of *GJD2*, *RASGRF1*, and *RFBOX1* and identification of 23 novel loci at genome-wide significance*: BICC1*, *BMP2*, *CACNA1D*, *CD55*, *CHD7*, *CHRNG*, *CYP26A1*, *GRIA4*, *KCNJ2*, *KCNQ5*, *LOC100506035*, *LAMA2*, *MYO1D*, *PCCA*, *TJP2*, *PTPRR*, *SHISA6*, *PRSS56*, *RDH5*, *RORB*, *SIX6*, *TOX*, and *ZMAT472*.[@i1552-5783-60-3-M89-b87]

Meanwhile, 23andMe performed a contemporaneous large GWAS on 55,177 individuals of European descent by using a survival analysis, based on the first release of 1000G[@i1552-5783-60-3-M89-b88] (a catalog of human genetic variation). Its analysis was based on self-reported presence of myopia and age of spectacle wear as a proxy for severity. 23andMe also replicated *GJD2*, *RASGRF1*, and *RFBOX1* and identified 11 new loci: *BMP3*, *BMP4*, *DLG2*, *DLX1*, *KCNMA1*, *LRRC4C*, *PABPCP2*, *PDE11A*, *RGR*, *ZBTB38*, *ZIC2*.[@i1552-5783-60-3-M89-b89] Of the 22 loci discovered by CREAM, 8 were replicated by 23andMe, and 16 of the 20 loci identified by 23andMe were confirmed by CREAM. This was surprising, as the studies used very different phenotyping methods. In addition, the effect sizes of 25 loci were very similar, despite analyses on different scales: diopters for CREAM and hazard ratios for 23andMe.[@i1552-5783-60-3-M89-b90] After these two publications, replication studies provided validation for *KCNQ5*, *GJD2*, *RASGRF1*, *BICC1*, *CD55*, *CYP26A1*, *LRRC4C*, *LAMA2*, *PRSS56*, *RFBOX1*, *TOX*, *ZIC2*, *ZMAT4*, and *B4GALNT2* in per-SNP analyses, and for *GRIA4*, *BMP2*, *BMP4*, *SFRP1*, *SH3GL2*, and *EHBP1L1* in gene-based analyses.[@i1552-5783-60-3-M89-b91][@i1552-5783-60-3-M89-b92][@i1552-5783-60-3-M89-b93][@i1552-5783-60-3-M89-b94][@i1552-5783-60-3-M89-b95]--[@i1552-5783-60-3-M89-b96]

Although CREAM and 23andMe found a large number of loci, only approximately 3% of the phenotypic variance of refractive error was explained.[@i1552-5783-60-3-M89-b87],[@i1552-5783-60-3-M89-b89] Larger GWAS meta-analyses were clearly needed, and the two large studies combined efforts. This new GWAS meta-analysis was based on the phase 1 version 3 release of 1000G, included 160,420 participants, and findings were replicated in the UK Biobank (95,505 participants). Using this approach, the number of validated refractive error loci increased to 161. A high genetic correlation between European and Asian individuals (\>0.78) was found, implying that the genetic architecture of refractive error is quite similar for European and Asian individuals. Taken together, these genetic variants accounted for 7.8% of the explained phenotypic variance, leaving room for improvement. Even so, polygenic risk scores, which are constructed by the sum of effect sizes of all risk variants per individual depending on their genotypes, were well able to distinguish individuals with hyperopia from those with myopia at the lower and higher deciles. Interestingly, those in the highest decile had a 40-fold greater risk of myopia. The predictive value (area under the curve) of these risk scores for myopia versus hyperopia, adjusted for age and sex, was 0.77 (95% CI 0.75--0.79).

The next step will include GWAS on even larger sample sizes. Although this will improve the explained phenotypic variance, it is unlikely that GWAS will uncover the entire missing heritability. SNP arrays do not include rare variants, nor do they address gene-environment and gene-gene interactions, or epigenetic effects.

### 8.1.3 GWAS on Refractive Error Endophenotypes {#s8a3}

As myopia is mostly due to increased axial length, researchers have used this parameter as a myopia proxy or "endophenotype." The first axial length GWAS examined 4944 individuals of East and Southeast Asian ancestry, and a locus on 1q41 containing the zinc finger pseudogene *ZC3H11B* reached genome-wide significance (*P* = 4.38 × 10^−10^).[@i1552-5783-60-3-M89-b82],[@i1552-5783-60-3-M89-b97] A much larger GWAS meta-analysis of axial length comprised 12,531 European individuals and 8216 Asian individuals.[@i1552-5783-60-3-M89-b93] This study identified eight novel genome-wide significant loci (*RSPO1*, *C3orf26*, *LAMA2*, *GJD2*, *ZNRF3*, *CD55*, *MIP*, *ALPPL2*), and also replicated the *ZC3H11B* gene. Notably, five of these loci had been associated with refractive error in previous GWAS.

Several relatively small GWAS have been performed for corneal curvature, and identified associations with *FRAP1*, *PDGFRA* (also associated with eye size), *CMPK1*, and *RBP3*.[@i1552-5783-60-3-M89-b93],[@i1552-5783-60-3-M89-b98][@i1552-5783-60-3-M89-b99][@i1552-5783-60-3-M89-b100]--[@i1552-5783-60-3-M89-b101] More recently Miyake et al.[@i1552-5783-60-3-M89-b101],[@i1552-5783-60-3-M89-b102] published a two-stage GWAS for three myopia-related traits: axial length, corneal curvature, and refractive error. The study was performed in 9804 Japanese individuals, with trans-ethnic replication in Chinese and Caucasian individuals. A novel gene, *WNT7B*, was identified for axial length (*P* = 3.9 × 10^−13^) and corneal curvature (*P* = 2.9 × 10^−40^), and the previously reported association with *GJD2* and refractive error was replicated.

8.2 Genome-Wide Pathway Analyses {#s8b}
--------------------------------

The main goal of GWAS is to improve insight on the molecules involved in disease, and help identify disease mechanisms. For myopia, a retina-to-sclera signaling cascade had been proposed for many years (see accompanying paper IMI -- Report on Experimental Models of Emmetropization and Myopia[@i1552-5783-60-3-M89-b103]), but knowledge on its molecular drivers was limited. Several attempts were made to translate the findings from refractive error GWAS into this cascade.[@i1552-5783-60-3-M89-b87],[@i1552-5783-60-3-M89-b89],[@i1552-5783-60-3-M89-b104] Here we provide an overview of genes annotated to the risk variants and their relationship to the underlying biological mechanism.

Deducted from the CREAM GWAS, pathways included neurotransmission (*GRIA4*), ion transport (*KCNQ5*), retinoic acid metabolism (*RDH5*), extracellular matrix remodeling (*LAMA2*, *BMP2*), and eye development (*SIX6*, *PRSS56*). Likewise, 23andMe proposed extracellular matrix remodeling (*LAMA2*, *ANTXR2*), the visual cycle (*RDH5, RGR*, *KCNQ5*), neuronal development (*KCNMA1*, *RBFOX1*, *LRRC4C*, *NGL-1*, *DLG2*, *TJP2*), eye and body growth (*PRSS56*, *BMP4*, *ZBTB38*, *DLX1*), and retinal ganglion cells (*ZIC2*, *SFRP1*)[@i1552-5783-60-3-M89-b105] as functions. Hysi et al.[@i1552-5783-60-3-M89-b106] performed pathway analyses using both the CREAM and 23andMe GWAS, and reported that plasma membrane, cell-cell adhesion, synaptic transmission, calcium ion binding, and cation channel activity were significantly overrepresented in refractive error in two British cohorts. Furthermore, by examining known protein-protein interactions, the investigators identified that many genes are related to cell-cycle and growth pathways, such as the MAPK and TGF-beta/SMAD pathways.

The latest update on pathway analysis in myopia stems from the meta-GWAS from CREAM and 23andMe.[@i1552-5783-60-3-M89-b24] TGF-beta signaling pathway was a key player; the association with the *DRD1* gene provided genetic evidence for a dopamine pathway. Most genes were known to play a role in the eye,[@i1552-5783-60-3-M89-b107] and most significant gene sets were "abnormal photoreceptor inner segment morphology" (Mammalian Phenotype Ontology \[MP\] 0003730; *P* = 1.79 × 10^−7^), "thin retinal outer nuclear layer" (MP 0008515), "detection of light stimulus" (Gene Ontology \[GO\] 0009583), "nonmotile primary cilium" (GO 0031513), and "abnormal anterior-eye-segment morphology" (MP 0005193). Notably, *RGR*, *RP1L1*, *RORB*, and *GNB3* were present in all of these meta-gene sets. Taken together, retinal cell physiology and light processing are clearly prominent mechanisms for refractive error development, and all cell types of the neurosensory retina, RPE, vascular endothelium, and extracellular matrix appear to be involved ([Fig. 3](#i1552-5783-60-3-M89-f03){ref-type="fig"}). Novel mechanisms included rod-and-cone bipolar synaptic neurotransmission, anterior-segment morphology, and angiogenesis.[@i1552-5783-60-3-M89-b24]

![Schematic overview of expression in retinal cells of refractive error and syndromic myopia genes according to literature. Bold: genes identified for both common refractive error and in syndromic myopia.](i1552-5783-60-3-M89-f03){#i1552-5783-60-3-M89-f03}

9. Whole-Exome and Whole-Genome Sequencing {#s9}
==========================================

Unlike GWAS, whole-exome sequencing (WES) and whole-genome sequencing (WGS) have the potential to investigate rare variants. Exomes are interesting, as they directly contribute to protein translation, but they constitute only approximately 1% of the entire genome. WGS allows for identification of variants across the entire genome, but requires a high-throughput computational infrastructure and remains costly.

WES has been conducted primarily in case-control studies of early-onset high myopia or in specific families with a particular phenotype (i.e., myopic anisometropia) or inheritance pattern (i.e., X-linked).[@i1552-5783-60-3-M89-b108][@i1552-5783-60-3-M89-b109][@i1552-5783-60-3-M89-b110]--[@i1552-5783-60-3-M89-b111] Several novel mutations in known myopia genes were identified this way: *CCDC111*,[@i1552-5783-60-3-M89-b109] *NDUFAF7*,[@i1552-5783-60-3-M89-b110] *P4HA2*,[@i1552-5783-60-3-M89-b108] *SCO2*,[@i1552-5783-60-3-M89-b112] *UNC5D*,[@i1552-5783-60-3-M89-b111] *BSG*,[@i1552-5783-60-3-M89-b113] *ARR3*,[@i1552-5783-60-3-M89-b114] *LOXL3*,[@i1552-5783-60-3-M89-b115] *SLC39A5*,[@i1552-5783-60-3-M89-b116] *LRPAP1*,[@i1552-5783-60-3-M89-b117] *CTSH*,[@i1552-5783-60-3-M89-b117] *ZNF644*.[@i1552-5783-60-3-M89-b118],[@i1552-5783-60-3-M89-b119] Although most genetic variants displayed an autosomal dominant hereditary pattern,[@i1552-5783-60-3-M89-b108],[@i1552-5783-60-3-M89-b112],[@i1552-5783-60-3-M89-b118],[@i1552-5783-60-3-M89-b119] X-linked heterozygous mutations were identified in *ARR3*, only in female family members.[@i1552-5783-60-3-M89-b114] The functions of these novel genes include DNA transcription (*CCDC111*, *ZNF644*), mitochondrial function (*NDUFAF7*, *SCO2)*, collagen synthesis (*P4HA2*), cell signaling (*UNC5D*, *BSG*), retina-specific signal transduction (*ARR3*), TGF-beta pathway (*LOXL3*, *SLC39A5*, *LRPAP1*), and degradation of proteins in lysosomes (*CTSH*). Jiang et al.[@i1552-5783-60-3-M89-b119] investigated family members with high myopia and identified new mutations in LDL receptor related protein associated protein 1 (*LRPAP1*), cathepsin H (*CTSH* ), zinc finger protein 644 isoform 1 (*ZNF644*), solute carrier family 39 (metal ion transporter) member 5 (*SLC39A5*), and SCO2, cytochrome c oxidase assembly protein (*SCO2*).[@i1552-5783-60-3-M89-b119]

Many clinicians have noticed that retinal dystrophies and ocular developmental disorders often coincide with myopia.[@i1552-5783-60-3-M89-b115] This triggered Sun et al.[@i1552-5783-60-3-M89-b120] to evaluate variants in a large number of retinal dystrophy genes in early-onset high myopia in 298 unrelated myopia probands and their families, and they thereby identified 29 potentially pathogenic mutations in *COL2A1*, *COL11A1*, *PRPH2*, *FBN1*, *GNAT1*, *OPA1*, *PAX2*, *GUCY2D*, *TSPAN12*, *CACNA1F*, and *RPGR*, and most had an autosomal dominant inheritance pattern. Kloss et al.[@i1552-5783-60-3-M89-b121] performed WES in 14 families with high myopia, and identified 104 new genetic variants located in both known MYP loci (e.g., *AGRN*, *EME1*, and *HOXA2*) and in new loci (e.g., *ATL3* and *AKAP12*).

To date, WGS has not been conducted for myopia or refractive error, most likely due to the reasons mentioned above. When costs for WGS decrease, these studies will undoubtedly be conceived.

10. Gene-Environment Interaction {#s10}
================================

It has become clear that environmental factors are driving the recent epidemic rise in the prevalence of myopia.[@i1552-5783-60-3-M89-b122][@i1552-5783-60-3-M89-b123][@i1552-5783-60-3-M89-b124][@i1552-5783-60-3-M89-b125]--[@i1552-5783-60-3-M89-b126] To date, the most influential and consistent environmental factor is education. Studies have estimated that individuals going onto higher education have double the myopia prevalence compared with those who leave school after only primary education.[@i1552-5783-60-3-M89-b127][@i1552-5783-60-3-M89-b128]--[@i1552-5783-60-3-M89-b129] Education has been a primary focus for gene-environment (GxE) interaction analyses in myopia. GxE studies have the potential to show modification of the effect of risk variants by environmental exposures, but can also reveal genetic associations that were hidden in unexposed individuals.

One of the first GxE studies for myopia investigated variants in matrix metalloproteinases genes (*MMP1*--*MMP10*). Two SNPs (rs1939008 and rs9928731) that were first found to be associated with refraction in Amish families were also associated in a lower but not in the higher education group of the Age-Related Eye Disease Study (AREDS) study. These results suggest that variants in these genes may play a role in refractive variation in individuals not exposed to myopic triggers.[@i1552-5783-60-3-M89-b59],[@i1552-5783-60-3-M89-b130] In contrast, a study combining human GWAS data and animal models of myopia provided an experimental example of GxE interaction involving a rare variant in the *APLP2-*gene only in children exposed to large amounts of daily reading.[@i1552-5783-60-3-M89-b131] In addition, an analysis performed in five Singapore cohorts found risk variants in *DNAH9*, *GJD2*, and *ZMAT4* that were more strongly associated in individuals who achieved higher secondary or university education.[@i1552-5783-60-3-M89-b132] Significant biological interaction between education and other risk variants was studied using a genetic risk score of all known risk variants at the time (*n* = 26) derived from the CREAM meta-GWAS.[@i1552-5783-60-3-M89-b133] European subjects with a high genetic load in combination with university-level education had a far greater risk of myopia than those with only one of these two factors. A study investigating GxE interactions in children and the major environmental risk-factors, nearwork, time outdoors, and 39 SNPs derived from the CREAM meta-GWAS revealed nominal evidence of interaction with nearwork (top variant in *ZMAT4*).[@i1552-5783-60-3-M89-b133],[@i1552-5783-60-3-M89-b134]

GEWIS, using all variants from the CREAM meta-GWAS, revealed three novel loci (*AREG*, *GABRR1*, and *PDE10A*) for GxE in Asian populations, whereas no interaction effects were observed in Europeans due to many reasons, such as the quantitative differences in the intensity of nearwork during childhood.[@i1552-5783-60-3-M89-b48] Up to now, there is no robust evidence that there are fundamental differences in the genetic background of myopia risk between European and Asian individuals.

11. Mendelian Randomization {#s11}
===========================

Mendelian randomization (MR) is a method that allows one to test or estimate a causal effect from observational data in the presence of confounding factors. MR is a specific type of instrumental variable analysis that uses genetic variants with well-understood effects on exposures or modifiable biomarkers.[@i1552-5783-60-3-M89-b135],[@i1552-5783-60-3-M89-b136] Importantly, the SNP must affect the disease status only indirectly via its effect on the exposure of interest.[@i1552-5783-60-3-M89-b137] MR is particularly valuable in situations in which randomized controlled trials are not feasible, where it is applied to help elucidate biological pathways.

Currently, three studies have been published on MR in refractive error and myopia. The first, published in 2016, explored the effect of education on myopia.[@i1552-5783-60-3-M89-b138] This study constructed polygenic risk scores of genetic variants found in GWAS for educational attainment, and used these as the instrumental variable. Subsequently, results of three cohorts (Cooperative Health Research in the Region Augsburg \[KORA\], AREDS, Blue Mountain Eye Study \[BMES\]; total *N* = 5649) were meta-analyzed. Strikingly, approximately 2 years of education was associated with a myopic shift of −0.92 ± 0.29 D (*P* = 1.04 × 10^−3^), which was even larger than the observed estimate. Similar results were observed in data from the UK Biobank study (*N* = 67,798); MR was performed and causality of education was tested for myopic refractive error bi-directionally.[@i1552-5783-60-3-M89-b139] Genetic variants for years of education from Social Science Genetic Association Consortium (SSGAC) and 23andMe studies were considered. Analyses of the observational data suggested that every additional year of education was associated with a myopic shift of −0.18 D per year (95% CI −0.19 to −0.17; *P* \< 2.0^−16^). MR suggested the true causal effect was stronger: −0.27 D per year (95% CI −0.37 to −0.17; *P* = 4.0^−8^). As expected, there was no evidence that myopia was a cause for education (*P* = 0.6). The conclusion from these studies was that education appears truly causally related to myopia, and effects calculated by the current observational studies may be underestimated.

Because several studies had proposed that vitamin D has a protective effect against myopia,[@i1552-5783-60-3-M89-b140][@i1552-5783-60-3-M89-b141]--[@i1552-5783-60-3-M89-b142] the third MR study investigated the causality of low vitamin D concentrations on myopia. Genetic variants of the *DHCR7*, *CYP2R1*, *GC*, and *CYP24A1* genes with known effects on serum levels of vitamin D were used as instrumental variables in a meta-analysis of refractive error in CREAM (*N*~EUR~ = 37,382 and *N*~ASN~ = 8,376). The estimated effects of vitamin D on refractive error were small in both ethnicities (Caucasians: −0.02 \[95% CI −0.09, 0.04\] D per 10 nmol/L increase in vitamin D concentration; Asian individuals: 0.01 \[95% CI −0.17, 0.19\] D per 10 nmol/L increase).These results suggest that the causal effect of vitamin D on myopia is very small, if any. Therefore, associations with vitamin D levels in the observational studies are likely to represent the effect of time spent outdoors.

12. Epigenetics {#s12}
===============

Epigenetic changes refer to functionally relevant changes to the genome that do not involve the nucleotide sequence of DNA. They represent other changes of the helix structure, such as DNA methylation and histone modification,[@i1552-5783-60-3-M89-b143] and these changes can regulate gene expression. Noncoding RNAs are small molecules that can also regulate gene expression, mainly at the posttranscriptional level; they can be epigenetically controlled but can also drive modulation of the DNA chromatin structure themselves.[@i1552-5783-60-3-M89-b144] Investigations into epigenetic changes of eye diseases still face some important technological hurdles. High-throughput next-generation sequencing technologies and high-resolution genome-wide epigenetic profiling platforms are still under development, and accessibility of RNA expression in human ocular tissues[@i1552-5783-60-3-M89-b145] is limited. Moreover, epigenetic changes are tissue- and time-specific, so it is essential to study the right tissue at the correct developmental stage. Animal models are often used as a first step before moving to humans, although epigenetic processes are not always conserved across species. Nevertheless, there have been some attempts to reveal epigenetic changes involved in myopia development.

A experiment using monocular form deprivation in a mouse model found that hypermethylation of CpG sites in the promoter/exon 1 of *COL1A1* may underlie reduced collagen synthesis at the transcriptional level in myopic scleras.[@i1552-5783-60-3-M89-b146] A human study analyzing myopic individuals found that methylation of the CpG sites of the CRYAA promotor leads to lower expression of *CRYAA* in human lens epithelial cells.[@i1552-5783-60-3-M89-b147]

Myopia studies evaluating the role of noncoding RNAs are more common. The latest GWAS meta-analysis found 31 loci residing in or near regions transcribing small noncoding RNAs, thus hinting toward the key role of posttranscriptional processes and epigenetic regulation.[@i1552-5783-60-3-M89-b24],[@i1552-5783-60-3-M89-b144] MicroRNAs (miRNAs) are the best-characterized family of small noncoding RNAs. In their mature form, they are approximately 19 to 24 nucleotides in length and regulate hundreds of genes. They are able to bind to 3′ untranslated regions (UTRs) on RNA polymers by sequence-specific posttranscriptional gene silencing; one miRNA can regulate the translation of many genes. miRNAs have been a hot topic in past years due to the potential clinical application of these small RNA sequences: accessibility of the retina for miRNA-based therapeutic delivery has great potential for preventing and treating retinal pathology.[@i1552-5783-60-3-M89-b148] In a case-control study, Liang et al.[@i1552-5783-60-3-M89-b149] identified a genetic variant, rs662702, that was associated with the risk of extreme myopia in a Taiwanese population. The genetic variant was located at the 3′-UTR of PAX6, which is decreased in myopia. rs662702 is localized near the seed region of miR-328, and the C \> T substitution leads to a mismatch between miR-328 and PAX6 mRNA. Further functional study indicated that the risk C allele reduced PAX6 expression relative to the T allele, which could result from knockdown effect of the C allele by miR-328. Therefore, reducing miR-328 may be a potential strategy for preventing or treating myopia.[@i1552-5783-60-3-M89-b61] Another study focused on miR-184. This miRNA is the most abundant one in the cornea and the crystalline lens, and sequence mutations have been associated with severe keratoconus with early-onset anterior polar cataract. Lechner et al.[@i1552-5783-60-3-M89-b149],[@i1552-5783-60-3-M89-b150] sequenced miR-184 in 96 unrelated Han southern Chinese patients with axial myopia, but no mutations were detected. Xie et al.[@i1552-5783-60-3-M89-b151] analyzed rs157907 A/G in miR-29a and rs10877885 C/T in let-7i in a severe myopia case-control study (*N*~cases~ = 254; *N*~controls~ = 300). The G allele of the rs157907 locus was significantly associated with decreased risk of severe myopia (*P* = 0.04), launching the hypothesis that rs157907 A/G might regulate miR-29a expression levels. Functional studies are needed to provide evidence for this theory.

13. Concluding Remarks {#s13}
======================

Research on myopia genetics, genetic epidemiology, and epigenetics is flourishing and is providing a wealth of new insights into the molecules involved in myopiagenesis. Despite this progress, the chain of events forming the myopia-signaling cascade and the triggers for scleral remodeling are still largely unknown. Next steps should include all the novel technological advances for dissecting complex disorders, such as expansion of omics (such as genomics, transcriptomics, proteomics, and metabolomics), using multisource study populations, environmental genomics, and systems biology to organically integrate findings and improve our understanding of myopia development in a quantitative way via big data analytics (i.e., combining multi-omics and other approaches with deep learning or artificial intelligence). Expanding our knowledge of pathologic mechanisms and ability to pinpoint at-risk individuals will lead to new therapeutic options, better patient management, and, ultimately, prevention of complications and visual impairment from myopia.
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